

REMARKS

Claims 1-81 are pending in this application and presented for examination. Claims 61-81 are newly added. Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version with markings to show changes made." Early examination on the merits is respectfully requested.

I. FORMALITIES


Support for the new claims 61-81 is found throughout the application as originally filed. More particularly, support for new claim 61 is found, for example, on page 4, lines 7-9; and claim 42 as filed. Support for claim 62 is found, for example, on page 17, lines 1-2. Support for claims 63-64 is found, for example, on page 15, bottom, bridging to page 16, lines 1-3. Support for claims 65-66 is found, for example, on page 20, lines 6-7. Support for claim 67 is found, for example, on page 13, lines 18-22. Support for claims 68-80 is found, for example, in claims 43-60 as originally filed. Support for claim 81 is found, for example, in claim 56.

As such, Applicants believe no new matter has been introduced, and respectfully request that the new claims be entered.

II. CONCLUSION

In view of the foregoing, Applicants respectfully request early action on the merits. If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 925-472-5000.

Respectfully submitted,



Joseph R. Snyder
Reg. No. 39,381

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (415) 576-0200
Fax: (415) 576-0300
JS
WC 9040291 v1

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Please add the following new claims 61-81:

- 1 **61.** (New) A method for treating bladder cancer by the administration
 2 of a recombinant viral vector encoding a cytostatic or a tumor suppressor gene in
 3 combination with a compound of Formula I:




4
 5 wherein:


6 m and n are the same or different and each is an integer from 2-8;

7 R is a cationic group or $\text{---}\overset{\text{O}}{\parallel}\text{C---X}_3$;

8 X₁ is a member selected from the group consisting of



11 and X₂ and X₃ are each independently selected from the group consisting of a saccharide,



1 **62.** (New) The method of claim **61**, wherein said adenoviral vector is
 2 selected from the group consisting of a replication competent viral vector, a replication
 3 deficient viral vector and a conditionally replicating viral vector.

1 **63.** (New) The method of claim **61**, wherein said tumor suppressor
 2 gene is selected from the group consisting of p53, p110Rb, p16, p21, p56Rb, p94Rb,
 3 Rb56, and a functional variant of the Rb gene and the p53 gene.

1 **64.** (New) The method of claim **63**, wherein said tumor suppressor
 2 gene is a functional variant of the Rb gene and the p53 gene.

1 **65.** (New) The method of claim **61**, wherein said administration of said
 2 compound of Formula I is prior to the administration of said recombinant viral vector.

1 **66.** (New) The method of claim **61**, wherein said administration of said
 2 compound of Formula I is concomitant with the administration of said recombinant viral
 3 vector.

1 **67.** (New) The method of claim **61**, wherein the administration of said
 2 compound of Formula I further comprises a solubilizing agent.

1 **68.** (New) The method of claim **61**, wherein R is a cationic group
 2 selected from the group consisting of NMe₃⁺ and NH₃⁺.

1 69. (New) The method of claim 61, wherein the saccharide group
2 comprises one or more pentose or hexose residues.

1 70. (New) The method of claim 61, wherein the saccharide group is
2 selected from the group consisting of pentose monosaccharide groups, hexose
3 monosaccharide groups, pentose-pentose disaccharide groups, hexose-hexose
4 disaccharide groups, pentose-hexose disaccharide groups, and hexose-pentose
5 disaccharide groups.


1 71. (New) The method of claim 61, wherein the saccharide group
2 comprises between three and about eight monosaccharide residues.

1 72. (New) The method of claim 61, wherein the saccharide group is a
2 trisaccharide.

1 73. (New) The method of claim 61, wherein at least one of X_2 and X_3
2 is a saccharide group.


1 74. (New) The method of claim 61, wherein m and n are each
2 independently 2 or 3.

1 75. (New) The method of claim 61, wherein X_1 and X_2 are both




2
3 and X_3 is a saccharide group.

- 1 76. (New) The method of claim 61, wherein said compound has
2 Formula III:



3


- 1 77. (New) The method of claim 61, wherein said compound has
2 Formula IV:



3

4

- 1 78. (New) The method of claim 61, wherein said compound has
2 Formula V:



V.


3

1

2

79. (New) The method of claim 61, wherein said compound has


Formula II:




3

4

wherein X₁ and X₂ are selected from the group consisting of a



and




5

6

and X₃ is a saccharide group.

1

80. (New) The method of claim 61, wherein X₁ and X₂ are both



and X₃ is a glucose group.

81. (New) A method for treating bladder cancer by the administration of a recombinant viral vector encoding a cytostatic or a tumor suppressor gene in combination with a compound of Formula III:

